Format

Send to

Choose Destination
Expert Rev Clin Immunol. 2014 Sep;10(9):1255-62. doi: 10.1586/1744666X.2014.932250. Epub 2014 Jul 29.

The role of immune and metabolic biomarkers for improved management of sepsis patients.

Author information

1
Department of Endocrinology, Diabetes and Clinical Nutrition, Medical University Clinic, Kantonsspital Aarau, Tellstrasse, 5001 Aarau, Switzerland.

Abstract

Sepsis, the body`s overwhelming response to systemic infections, is responsible for significant morbidity, mortality, and financial burden. Pathogens and their antigens stimulate pro- and anti-inflammatory mediators and immune markers which characterize the host defense and orchestrate leukocyte recruitment to the acute site of infection. Different immune and metabolic biomarkers have been studied in relation to sepsis for their diagnostic and/or prognostic aid. Recent studies have provided abundant evidence that specific immune and metabolic biomarkers improve a physician`s ability to guide early sepsis recognition, severity assessment and therapeutic decisions in individual patients. This may allow for a transition from bundled sepsis care (protocols combining several medical practices) to more individualized management. First, lactate has now been widely used for risk stratification and guidance of fluid resuscitation. Second, procalcitonin correlates with risks of bacterial infections and helps guide therapeutic decisions about initiation and withdrawal of anti-microbial therapy. Third, prognostic markers such as pro-adrenomedullin improve early mortality prediction and thereby site-of-care decisions in respiratory infections. For these markers interventional trials have documented their value when integrated in clinical protocols.

KEYWORDS:

adrenomedullin; antibiotic guidance; biomarker; lactate; pro-ADM; procalcitonin; sepsis

PMID:
25069484
DOI:
10.1586/1744666X.2014.932250
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center